Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

Aetna Settles FCA Allegations for $117.7 Million

By Ada Janocinska on March 13, 2026
Email this postTweet this postLike this postShare this post on LinkedIn

On March 11, the U.S. Department of Justice and U.S. Attorney’s Office announced that Aetna, a national health insurer, has agreed to pay $117,700,000 to settle alleged violations of the False Claims Act (FCA). The government was investigating Aetna for submitting inaccurate and untruthful diagnosis codes for its Medicare Advantage Plan beneficiaries, which increased Aetna’s reimbursement payments from Medicare.

Medicare Advantage Plans are offered by commercial insurers as an alternative for Medicare beneficiaries who opt out of traditional Medicare. The Centers for Medicare & Medicaid Services (CMS) reimburses the commercial insurers a fixed monthly amount that is based on certain risk and health factors of its Medicare Advantage Plan beneficiaries, which are largely determined by the diagnosis codes the Medicare Advantage insurer provides to CMS.

In the Aetna investigation, the government reviewed claims that dated back to 2015, and determined that Aetna had submitted diagnosis codes that were not substantiated by the patients’ medical records. Similarly, for payment years 2018 through 2023, the investigation identified inaccurate diagnosis codes that Aetna submitted for morbid obesity where, in fact, the patients’ BMI (body mass index) was not consistent with such diagnosis.

Acting Deputy Inspector General for Investigations, Scott J. Lampert, of the U.S. Department of Health and Human Services, Office of Inspector General commented that this Aetna settlement “makes clear that no company is beyond accountability, no matter how large or well known.”

Sign up to receive Rivkin Rounds at www.RivkinRounds.com.

Photo of Ada Janocinska Ada Janocinska
Email
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Rivkin Rounds
  • Organization:
    Rivkin Radler
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo